Retension Pharmaceuticals, Inc. (RTSN) company profile
Close on Nov 18, 2026Market cap $11.22MP/E –Yield –
About Retension Pharmaceuticals
Pharmaceutical Preparations, SIC 2834
Retension Pharmaceuticals, Inc. is listed on Nasdaq under the ticker RTSN, in the SEC industry Pharmaceutical Preparations. It is incorporated in Delaware and its fiscal year ends on December 31. Reported financials on StockData start in fiscal 2024.
Company profile
Company
- Legal name
- Retension Pharmaceuticals, Inc.
- Headquarters
- Mclean, VA
- Address
- C/O Redux Therapeutics, Llc, 902 Turkey Run Road 22101
- Phone
- (703) 624-2024
- Website
- retensionpharmaceuticals.com
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
Stock & identifiers
- Ticker
- RTSN
- Exchange
- Nasdaq
- IPO date
- Oct 9, 2026
- Filer category
- <br>Emerging growth company
- SEC CIK
- 2002988
- CUSIP
- 76135H100
- ISIN
- US76135H1005
- FIGI
- BBG01PDS76B4
- Share class FIGI
- BBG01PDS76H8
- LEI
- 529900QBUEUWO67CZD11
- EIN
- 93-2592788
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Eric L. Keller | CHIEF EXECUTIVE OFFICER, Director | 464,407 |
| Robert Wong | VP, Chief Accounting Officer | – |
| Sabine Bisson | CHIEF OPERATING OFFICER | 4,115 |
| Paul Sweetnam | CHIEF SCIENTIFIC OFFICER | 409,243 |
| Alison D. Schecter | Chief Medical Officer | – |
| Alexander Duke Schwartz | Chief Financial Officer | – |
| Michael J. Berendt | Director | 6,666 |
| Franklin M. Berger | Director | 22,517 |
| Donald Olds | Director | 5,637 |
| Pavan Cheruvu | Director | – |
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Oct 9, 2026
- Offer price
- $12.00
- Securities offered
- 3,750,000
- Gross proceeds
- $45.00M
- Exchange
- Nasdaq
- First trading day
- Oct 9, 2026
- First-day close
- $10.53-12.3%
- Lock-up ends (est.)
- Apr 7, 2027
“_____________________ Per Share Total Initial public offering price $ 12.00 $ 45,000,000 Underwriting discounts and commissions (1) $ 0.84 $ 3,150,000 Proceeds to us, before expenses $ 11.16 $ 41,850,000 ____________ (1) We have agreed to reimburse the underwriters for certain expenses.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Oct 9, 2026 | IPO | Initial public offering priced (424B4 prospectus) |
| Oct 8, 2026 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?